Mandate

Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Related

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024

Vinge advises Sobro in connection with investment in Clinton Marine Survey

Clinton Marine Survey has chosen to broaden its ownership with Sobro as a new partner and majority shareholder. All existing owners remain as significant shareholders. Clinton Marine Survey offers high quality hydrographic and geological surveys for navigation, dredging operations, mapping, marine construction and more.
April 09, 2024

Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III

Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fund III. The fund closed successfully with commitments of approximately SEK 1.5 billion from an international investor base consisting of a number of leading financial institutions. The investor interest in the fund raising was very strong, and the fund was significantly oversubscribed.
April 05, 2024